Search Results

PellePharm, Inc., a BridgeBio Pharma, Inc. company, today announced the presentation of various data highlighting product candidate patidegib topical gel for adults with Gorlin syndrome and high-frequency basal cell carcinoma (HF-BCC). The presentations will be made during the 29th Congress of the European Academy of Dermatology and Venereology (EADV), to be held virtually October 29 – 31, 2020. Patidegib topical gel

LEO Pharma A/S acquires minority stake in PellePharm and provides additional non-dilutive capital to fund PellePharm development programs; obtains option to acquire all shares in PellePharm

PellePharm, Inc., a BridgeBio Pharma, Inc. company, announced the completion of enrollment for its pivotal Phase 3 clinical trial of Patidegib Topical Gel 2% vs. vehicle gel in patients with Gorlin Syndrome.

Phyton Biotech and PellePharm today announced an exclusive partnership to develop a plant cell culture-based process to enable the future renewable production of the raw material for PellePharm’s patidegib, an investigational topical therapy for Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC)

PellePharm, Inc., a BridgeBio Pharma, Inc. company, announced it has dosed the first two participants in a Phase 2 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel for people with non-Gorlin High Frequency Basal Cell Carcinoma.

Denmark-based LEO Pharma and California rare disease drugmaker PellePharm entered into a strategic collaboration worth $760 million to address unmet needs in multiple orphan skin diseases, such as Gorlin Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), two rare forms of skin cancer.